Literature DB >> 12110487

Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).

E Van Cutsem1, M Dicato, J Wils, D Cunningham, E Diaz-Rubio, B Glimelius, D Haller, P Johnston, D Kerr, C H Koehne, R Labianca, B Minsky, B Nordlinger, A Roth, P Rougier, H J Schmoll.   

Abstract

This article summarises the progress that has been made in the adjuvant treatment of colorectal cancer over the last decade. In view of the consequent improvements in recurrence rates and in overall survival, the development of effective adjuvant treatments for colorectal cancer is considered as one of the most important to be made in clinical oncology over the last decade. Treatment recommendations based on evidence-based data and on expert opinions are summarised in this manuscript. However, a consensus cannot be reached on all aspects of treatment because of data that is currently emerging that will influence clinical practice and because of the many ongoing clinical trials. Those involved in the treatment of colorectal cancer should therefore be encouraged to continue to provide optimal patient care and to participate in well designed clinical trials in order to increase the evidence upon which they can base their clinical judgements and in order to make further progress.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110487     DOI: 10.1016/s0959-8049(02)00122-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling.

Authors:  E A Gaffney
Journal:  J Math Biol       Date:  2003-10-27       Impact factor: 2.259

2.  Bax expression is a candidate prognostic and predictive marker of colorectal cancer.

Authors:  Venkat R Katkoori; Catalina Suarez-Cuervo; Chandrakumar Shanmugam; Nirag C Jhala; Tom Callens; Ludwine Messiaen; James Posey; Harvey L Bumpers; Sreelatha Meleth; William E Grizzle; Upender Manne
Journal:  J Gastrointest Oncol       Date:  2010-12

3.  TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model.

Authors:  Grigore Cernaianu; Sibylle Frank; Katrin Erbstösser; Sandy Leonhardt; Michael Cross; Zoe McIvor; Gabriele Scholz; Temuujin Dansranjavin; Ilhan Celik; Andrea Tannapfel; Christian Wittekind; Ralf-Bodo Troebs; Karin Rothe; Joachim Bennek; Johann Hauss; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2005-06-04       Impact factor: 2.571

4.  Reg4-induced mitogenesis involves Akt-GSK3β-β-Catenin-TCF-4 signaling in human colorectal cancer.

Authors:  Kumar S Bishnupuri; Satheesh K Sainathan; Kislay Bishnupuri; Devon R Leahy; Qizhi Luo; Shrikant Anant; Courtney W Houchen; Brian K Dieckgraefe
Journal:  Mol Carcinog       Date:  2013-10-22       Impact factor: 4.784

5.  Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.

Authors:  Hong-Hwa Chen; William Tzu-Liang Chen; Hsin-Chung Lee; Jen-Kou Lin; Chuan-Yin Fang; Yenn-Hwei Chou; Peng-Chan Lin; Bo-Wen Lin; Chi-Chou Huang; Chung-Hung Yeh; Hsi-Hsien Hsu; Hung-Chang Chen; Wen-Chien Ting; Ming-Chin Yang; Elise Chia-Hui Tan
Journal:  Qual Life Res       Date:  2014-08-07       Impact factor: 4.147

6.  Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer.

Authors:  Sun Hee Jee; Sun Mi Moon; Ui Sup Shin; Hoe Min Yang; Dae-Yong Hwang
Journal:  J Korean Soc Coloproctol       Date:  2011-12-31

7.  Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Authors:  J Cassidy; J-Y Douillard; C Twelves; J J McKendrick; W Scheithauer; I Bustová; P G Johnston; K Lesniewski-Kmak; S Jelic; G Fountzilas; F Coxon; E Díaz-Rubio; T S Maughan; A Malzyner; O Bertetto; A Beham; A Figer; P Dufour; K K Patel; W Cowell; L P Garrison
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

8.  Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II).

Authors:  J Widder; F Herbst; W Dobrowsky; R Schmid; B Pokrajac; B Jech; C Chiari; A Stift; A Maier; J Karner-Hanusch; B Teleky; F Wrba; R Jakesz; R Poetter
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

9.  Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.

Authors:  Hyun-Sook Son; Woo Yong Lee; Won-Suk Lee; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

10.  Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.

Authors:  P Osterlund; T Ruotsalainen; R Korpela; M Saxelin; A Ollus; P Valta; M Kouri; I Elomaa; H Joensuu
Journal:  Br J Cancer       Date:  2007-09-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.